EDMOND PHARMA

Overview

EDMOND PHARMA is an active pharmaceutical ingredient (API) supplier with 10 active FDA Type II Drug Master Files, covering CHLOROPROCAINE HYDROCHLORIDE; CLENBUTEROL HYDROCHLORIDE; DEXMEDETOMIDINE HCL; ISOPROTERENOL HYDROCHLORIDE; LEVOBUPIVACAINE HYDROCHLORIDE; LURASIDONE HYDROCHLORIDE.

API / Drug Master Files

EDMOND PHARMA holds 10 active (11 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• CLENBUTEROL HYDROCHLORIDEActive2024-12-09
• LEVOBUPIVACAINE HYDROCHLORIDEActive2023-09-26
• CHLOROPROCAINE HYDROCHLORIDEActive2021-04-21
• ROPIVACAINE HYDROCHLORIDE MONOHYDRATEActive2020-12-21
• NORADRENALINE BITARTRATE MONOHYDRATEActive2019-07-31
• ISOPROTERENOL HYDROCHLORIDEActive2017-05-15
• LURASIDONE HYDROCHLORIDEActive2014-09-30
• DEXMEDETOMIDINE HCLActive2013-03-12
• TULOBUTEROL BASEActive2008-06-27
• MIDODRINE HYDROCHLORIDEActive2002-06-21
• CARTEOLOL HYDROCHLORIDEInactive1997-10-23

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to EDMOND PHARMA in our records. PharmaTek screens the full directory against live FDA enforcement data.